Literature DB >> 4011138

Tear diluents in the treatment of keratoconjunctivitis sicca.

J P Gilbard, K R Kenyon.   

Abstract

To determine the optimum solution concentration for lowering elevated tear film osmolarity in keratoconjunctivitis sicca (KCS), tear osmolarity was measured in four KCS patients before and after instillation of either an isotonic saline solution or one of four hypotonic saline solutions (range, 75-225 mOsm/L). Average tear osmolarity one minute after instillation was significantly lower with the hypotonic solutions than with the isotonic saline (mean +/- SEM, 290 +/- 3 mOsm/L vs. 317 +/- 1 mOsm/L, P less than 0.0005). Solutions 150 mOsm/L or less were most effective in lowering osmolarity; the 75 mOsm/L solution was occasionally associated with irritation. In 16 KCS patients, we then compared the therapeutic efficacy of the 150 mOsm/L solution with that of an otherwise identical isotonic solution in a two-week, double-masked, crossover study. The 150 mOsm/L solution was superior for symptom relief by nearly 2:1 (P = 0.01).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4011138     DOI: 10.1016/s0161-6420(85)33986-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Tear osmolarity variation in the dry eye.

Authors:  R L Farris; R N Stuchell; I D Mandel
Journal:  Trans Am Ophthalmol Soc       Date:  1986

Review 2.  Diagnostic methods and treatment modalities of dry eye conditions.

Authors:  F J Holly
Journal:  Int Ophthalmol       Date:  1993-06       Impact factor: 2.031

3.  TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells.

Authors:  Zan Pan; Zheng Wang; Hua Yang; Fan Zhang; Peter S Reinach
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

4.  Effect of osmolarity of artificial tear drops on relief of dry eye symptoms: BJ6 and beyond.

Authors:  P Wright; M Cooper; A M Gilvarry
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.